




# AUSTRALIA-TAIWAN CLINICAL TRIALS AND BIOTECH FORUM

24 JULY 2024



AUSTRALIA







Supported by

# Investment NSW



## Investment NSW

Part of the New South Wales Government

-  Lawrence Chang, NSW Trade and Investment Director Taipei Post
-  +886 2 8758 4215
-  [lawrence.chang@austrade.gov.au](mailto:lawrence.chang@austrade.gov.au)  
[lawrence.chang@investment.nsw.gov.au](mailto:lawrence.chang@investment.nsw.gov.au)
-  [investment.nsw.gov.au](http://investment.nsw.gov.au)

## Company Introduction

### New South Wales, Australia: A global hub for health and life sciences

With Australia's largest population, strongest economy, and innovative life sciences sector, New South Wales (NSW) is home to an integrated, world-class health and medical research sector that is solving some of the world's most complex and burdensome healthcare challenges. With leading research capability and fast-growing life sciences industry, NSW offers advanced products and unparalleled investment opportunities for industry.

### About Health and Life Sciences in NSW



The NSW public health care system offers world-class care to our 8 million citizens through 228 public hospitals and ranks 3rd as the most efficient healthcare system in the world.



NSW Government has committed to annual operating budget of AU\$33.5 billion (2022-23 budget) for Health, including \$2.8 billion for capital works to continue building and redeveloping hospitals and health facilities, delivering improved health outcomes for NSW families and communities.



NSW is home to 11 universities, with 2 universities in the world's top 20, the University of Sydney and the University of New South Wales (UNSW), NSW offers an ongoing pipeline of talent and research output, spurring the next wave of innovation.



Australia is ranked 9th in the world for life sciences research and government research and development tax incentives for eligible companies make early-phase clinical trials up to 60% cheaper to run in Australia than the US.



NSW is investing in Health Precincts to deliver health research, education and innovation. Health Precincts are agglomerations of tertiary referral hospitals, laboratories, medical research institutions, universities, industry and innovation spaces. They train the future workforce, generate employment, inspire innovation, foster collaboration between businesses of all sizes and create investment opportunities.



Major Health Precincts are located in Sydney, Westmead, Randwick, Macquarie Park, Liverpool, St Leonards and Darlinghurst, along with regional areas such as Newcastle, Wollongong and beyond.

### **Working with business to promote growth**

The NSW Government is targeting investment to grow the health and life sciences industry, through projects such as Sydney's AU\$96 million RNA pilot manufacturing centre (based at Macquarie Park), and AU\$134 million to support the first GMP-grade clinical and commercial viral vector manufacturing facility in Westmead.

The Sydney Biomedical Accelerator (due for completion by 2027) is a collaboration between the University of Sydney, the Sydney Local Health District, and several other partners, including industry and philanthropic

organisations. This world-class facility will provide industry an opportunity to collaborate with key researchers in the fields of cancer, cardiovascular disease, infectious diseases and immunity, and neuroscience and mental health.

The Medical Devices Fund is an ongoing \$8 million per year, competitive technology development and commercialisation program for new-to-world medical devices. The program is funded by NSW Health and administered by the Office for Health and Medical Research (OHMR).

NSW is looking for industry partnerships and investment opportunities across a broad range of areas including:

- medical devices (including laboratory diagnostics),
- digital health,
- advanced manufacturing (including genomic medicine and phage therapies)
- and clinical trials.

Investment NSW works closely with NSW Health and industry to commercial opportunities in these fields.

With business, hospitals, universities, clinics, and research institutes collaborating across multiple dedicated locations, NSW is leading the way to a healthier future for everyone. NSW is open for business, and we welcome you to join us in driving innovation and improving health outcomes.





# Australian companies



👤 Sharon Sim, Senior Business Development Manager

☎ +61 4 2353 6881

✉ Sharon.sim@360biolabs.com

🌐 360biolabs.com

## Company Introduction

---

360biolabs is Australia's most comprehensive speciality laboratory services company, providing bioanalytical clinical trial support for development of new therapeutics, vaccines and diagnostics in a quality-assured environment. We support pharmacokinetic (PK) analysis (small molecule, peptide and biologics), a diverse range of pharmacodynamic (PD) endpoints (including but not limited to flow cytometry, cytokine profiling, virus neutralisation, ELISPOT, qPCR, virological endpoints etc) and central lab services. 360biolabs provides a single laboratory for all of your global clinical trial requirements (Phase 1-4). Our quality systems include internationally recognised accreditation (GLP, ISO / IEC 17025,

ISO 15189), we have an industry experienced management team and industry standard and regulator compliant reporting.

360biolabs are part of the BioAgilytix global network. We offer the full spectrum of bio-analytical lab services for small and large molecules in all phases of drug development. Our labs are located in Durham, Boston, San Diego, Hamburg, Melbourne, and Brisbane.

BioAgilytix is a leading contract research organisation specialising in small and large molecule needs, enabling scientific innovators to develop and deliver game-changing biologic innovations through our expertise.

## Areas of Interest in Taiwan

---

Clinical Trial, Pharmacodynamics, Pharmacokinetics, Bispecific, Cell and Gene Therapy, Small molecules, Virology

**ACCLIME**

**ACCLIME** .

👤 Luis Silva, Regional Business Development Manager

☎ +66 96 807 6077

✉ l.silva@acclime.com

🌐 australia.acclime.com

## Company Introduction

---

Acclime Australia provides incorporation, compliance, accounting, tax, and advisory services for life science companies doing clinical trials in Australia that have also decided to access the country's R&D incentive program, which can give 43.5 cents cash back all every dollar spent on eligible R&D in Australia.

Acclime also has decades of experience working with clients in the life sciences and healthcare space - across a range of therapeutic areas - in providing both Market Entry Advisory Services and post-market entry Corporate Services throughout Asia, including:

- Opportunity assessment and pre-sales advice
- Strategic road maps and business plans
- Company incorporations, Resident Directors, Accounting & Tax services, etc

Our Market Entry Advisory Service offering includes advising on partnerships from preclinical evaluation to post-marketing commercialisation, thereby covering all clinical trial phases (I to IV). Acclime has also managed product registrations and other macro regulatory requirements for new drugs and devices across Asia.

## Areas of Interest in Taiwan

---

To meet with life science companies looking to enter the Australian market, whether to conduct R&D, invest in an asset, or set up a local presence for sales and marketing activities.

To meet with life science companies looking to expand into any of Acclime's 15 Asian markets. We provide a complete suite of Market Entry Advisory Services, along with in-country Corporate Services to establish and maintain a company for R&D or sales and distribution purposes.

# Aeterna Health Services



👤 Riddick Jie, Director  
☎ +61 433 839 680  
✉ Riddick@aeternahealth.com.au  
🌐 aeternahealth.com.au

## Company Introduction

---

Aeterna Health, based in Melbourne and established in 2017, is at the forefront of advanced regenerative medicine. We specialise in pioneering stem cell applications (svCell) and immune cell applications (iCell). Our svCell technology leads innovative treatments, including applications for osteoarthritis, and is implemented at St Vincent's Hospital Werribee. Our iCell technology ensures the preservation of vital immune cells for future therapeutic use and supports advanced

immune cell therapies. Our state-of-the-art cellular biology laboratory at La Trobe University drives research and develops new therapies for a variety of diseases. Additionally, we offer comprehensive preventive health services through our HealthScreen program, which provides high-precision cancer screening with micron-level MRI technology. At Aeterna Health, we are committed to improving lives through cutting-edge medical innovations and rigorous scientific research.

## Areas of Interest in Taiwan

---

Immune and stem cell therapies.



👤 Amilia Wee, Senior Business Development Manager

☎ +65 8345 6011

✉ Amilia.wee@agilexbiolabs.com

🌐 agilexbiolabs.com

## Company Introduction

---

Agilex Biolabs is Australia's largest bioanalytical and toxicology laboratory with close to 30 years' experience in regulated bioanalysis.

Our world-class laboratories feature state-of-the-art equipment, including Sciex Triple Quad 6500+, Gyrolab xPlore, MSD Quickplex 120, BD FACSymphony A3 and droplet digital PCR for a wide range of bioanalytical needs. Furthermore, Agilex Biolabs has ISO/IEC17025 accreditation and OECD GLP recognition with NATA to ensure that quality standards are met for pre-clinical to clinical analysis.


Agilex Biolabs also offers a range of toxicology services at our established GLP facility located in Brisbane, Australia. Services include exploratory toxicology and pharmacokinetics studies, and GLP toxicology services. We have expertise with all types of molecules, laboratory species, routes of administration, and non-clinical studies.

A global leader in providing flexible solutions, Agilex Biolabs has accelerated numerous biopharmaceutical and pharmaceutical drug development programs from US, APAC and EU.

## Areas of Interest in Taiwan

---

Preclinical, clinical trials, drug development, regulated bioanalysis, toxicology, small molecules, biologics, biomarkers, immunogenicity, oncology, central lab



# Avance Clinical CRO



AVANCE CLINICAL

👤 Andy Hu, Business Development Manager

☎ +61 4 3246 7426

✉ andy.hu@avancecro.com

🌐 avancecro.com

## Company Introduction

---

The full-service Contract Research Organization (CRO) with operations in Australia, New Zealand, Asia, North America, and Europe.

We specialize in delivering world-class operations, providing biotechs with strategic guidance from their early pre-clinical development with our experienced ClinicReady team through to late-phase studies, supported by our proven GlobalReady team. Our focus is on fast, agile, and adaptive operations that are solution-oriented, innovative, and cost-

effective, ensuring rapid results and robust data.


With a proven track record and experience spanning across more than 120+ indications, Avance Clinical consistently delivers high-quality data that is accepted by global regulators, including but not limited to the TGA, FDA, MHRA, EMA, MFDS, PDMA.

Avance Clinical distinguishes itself by its commitment to personalized service rather than a one-size-fits-all approach.

## Areas of Interest in Taiwan

---

Taiwanese biotechs, asian biotechs, Phase I and Phase II, European CROs interested in Taiwan market



# Biointelect



👤 Jacqui Wade, Director, Clinical Affairs & Director Services

☎ +61 4 1920 3652

✉ [jwade@biointelect.com](mailto:jwade@biointelect.com)

🌐 [biointelect.com](http://biointelect.com)

## Company Introduction

---

Biointelect is a life-science accelerator consultancy and CRO. Our deep knowledge of the innovation ecosystem, local and global reach, and experience from research to commercialisation provide our clients with confidence in the success of their goals.


By offering experience-driven strategic advice and technical support across the full innovation journey Biointelect develop and drive strategy, identify and evaluate new business opportunities and engage the right partners for our clients.

Biointelect's comprehensive suite of services encompasses the full product development cycle—from early phase research to market launch. This includes Strategy and Planning, Commercialisation Strategy, Regulatory Strategy, Director Services, Clinical Research (full-service CRO capabilities), Patient Access and Health Economics, and Health Technology Assessments and Policy Services, enabling our clients to devote their time to their core research and development interests.

## Areas of Interest in Taiwan

---

Biotech CRO services, Commercialisation, Regulatory Affairs



# CMAX Clinical Research



👤 Chris Saracini, Business Development Manager

☎ +61 0 431 244 785

✉ Chris.saracini@cmx.com.au

🌐 cmx.com.au

## Company Introduction

---

CMAX Clinical Research has been a leader in delivering early phase clinical trials for 30 years, making it one of the most respected clinical trial businesses in Australia.

Our modern custom-built facility is equipped with 78 inpatient beds and located opposite Adelaide's Bio-Med City, providing ready access to state-of-the-art facilities, equipment and world-class medical specialists.

Australian clinical trials are known for their quick start-up timelines, cost competitiveness and for their quality. CMAX's services are eligible for the generous Australian R&D Tax Incentive scheme. Australian data is internationally recognised by the FDA and other regulatory agencies.

## Areas of Interest in Taiwan

---

We are interested in potential collaborations with Taiwanese and other international biopharmaceutical companies who are

preparing for early phase clinical trials and are interested in the benefits of conducting their trial in Australia.



# CSI Medical Research



**CSI Medical Research**  
*A ClinChoice Company*

👤 Erika Visser, Country Manager  
(ANZ)

☎ +61 411 831 497

✉ erika@csimedicalresearch.com

🌐 csimedicalresearch.com

## Company Introduction

---

Clinical Solutions Innovating Medical Research aka CSI Medical Research Pte Ltd (CSI MR) is a contract research organisation (CRO) providing innovative, cost-effective, and efficient clinical solutions since 2017. We believe in implementing innovative automation by focusing on patient safety and care in clinical trials. CSI MR has extensive industry experience and knowledge of local practices, regional ethics, regulatory requirements, and site operations, making us your preferred strategic partner. We hope to aid more companies to confidently enter the ASEAN market with us

for innovative and cost-effective solutions. We provide clinical research services from strategy and proof of concept to medical writing, project management, clinical operations, pharmacovigilance, medical monitoring, data management and market authorization.

On 14<sup>th</sup> Jan 2024, CSI MR was acquired by Clinchoice Inc, a leading global CRO, contributing to the expansion of Clinchoice's global footprint throughout Asia, Europe, and North America.

## Areas of Interest in Taiwan

---

Clinical trials, pharmaceutical, medical devices, medical innovations, market authorization



# George Clinical



*Science. Service. Solutions.*

👤 Jake Lee, Head of Business Development, East Asia

☎ +82 10 3039 0642

✉ jlee@georgeclinical.com

🌐 georgeclinical.com

## Company Introduction

---

Founded in Asia-Pacific and driven by scientific expertise and operational excellence, George Clinical has been a leading, global clinical research organization for more than 20 years. With over 500 experienced people in 40 locations able to manage clinical trials in up to 70 geographies throughout the Asia-Pacific region, USA and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device and diagnostic customers, for all phases, registration and post-marketing trials.

George Clinical provides a full scope CRO services. We have the flexibility to provide single services as well as a full scope trial management solution to suit the requirements of our clients ranging from biotech start-ups, pharmaceutical, medical devices, and academic institutions.

Our unique value proposition combines scientific expertise with operational excellence. Through our panel of scientific leaders, many of whom are leading thought leaders in their respective fields, we have access to extensive investigator networks in a number of therapeutic areas including kidney & metabolic, cardiovascular, neurology and oncology.

Australia offers unique advantages for Taiwanese pharmaceuticals and biotech companies conducting early phase studies with its fast start-up timeline, well established Phase I units, experienced investigators, high quality data that is well recognized globally and an attractive R&D tax incentive scheme. George Clinical are well positioned to help Taiwanese sponsors take advantage of these operational benefits and look forward to having those conversations with the biotech, pharma, and medical devices companies at BIO-Taiwan.

## Areas of Interest in Taiwan

---

Clinical Trial in global and Australia

# Global R&D



👤 Dr Pavel Reddy, R&D Tax Advisor

☎ +61 – 415 557 542

✉ pavel@globalrnd.com.au

🌐 globalrnd.com.au

## Company Introduction

---

Global R&D is a dedicated R&D Tax Incentive consultancy with a truly global reach. We provide valuable, expert guidance on all aspects of R&D Tax matters to companies across Australia, China, EU, Singapore, South Korea, and USA.

Global R&D provides R&D Tax Advisory services across the various Tech sectors, including but not limited to BioTech, MedTech, and Pharma.

In addition to providing insightful and expert advice, trusted guidance, and focused resources to ensure compliant R&D Tax

Incentive claims, Global R&D has already enabled clients to receive cash refunds that exceed client expectations.


Founder and Director, Dr Pavel Reddy comes with 16+ years of R&D Tax expertise, and is currently registered with the Australian Government's Tax Practitioners Board.

Global R&D is in regular contact with the regulatory bodies, the Australian Taxation Office and AusIndustry, enabling clients to keep abreast with relevant information relating to the R&D Tax Incentive program.

## Areas of Interest in Taiwan

---

Biotech, MedTech, Medical Devices, Pharma, Clinical Trials





👤 Dr Robert Lin, CEO

☎ +61 2 9191 0640

✉ Robert.Lin@greenlightclinical.com

🌐 greenlightclinical.com

## Company Introduction

---

GreenLight Clinical (GLC) is a physician-led full service

clinical CRO established in 2006. Combining medical expertise, deep industry knowledge, and a close relationship with clinical research sites, GLC provides customized clinical research solutions to expedite pharmaceutical and biotech product development at high standards of quality and ethics in clinical research.

Our head office is based in Australia however, we have teams in the USA and Asia. One

of the key drivers to success for your trial lies in our relationships with sites within our clinical research network. With key members of our team previously working at trial sites, we understand the importance of good communication and collaboration with key stakeholders. This provides us with an opportunity to consult with key opinion leaders to help develop your study early on to ensure trial success. With this deeper understanding site capabilities and limitations, we can select the most appropriate sites for your trial.

## Areas of Interest in Taiwan

---

Specialist knowledge and experience in ophthalmology, oncology, rare and infectious diseases and medical devices.

- First-in-Human / First-In-Class
- New drugs & devices
- Phase I / Phase II /Regional Phase III

- Translation from healthy volunteers to in-patient populations
- Smooth transition from Australia to US based studies
- access to the largest Ophthalmology and Oncology site networks

# Harvest Integrated Research Organization



👤 Ya-Han Chang, Vice President of Commercial Strategy

☎ +886 2 2726 0028

✉ yahan.chang@harvestiro.com

🌐 en.harvestiro.com

## Company Introduction

---

Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative CRO, offering comprehensive cross-border solutions. With integrated capabilities and extensive expertise, we provide a full suite of services, including pre-clinical planning, trial design, regulatory affairs, pharmacovigilance, statistics, data management, project management, and clinical monitoring.

For over 20 years, our ANZ team has been at the forefront of leveraging Australia's advantages for clinical trials. With deep knowledge in diverse therapeutic areas and

experience in the international pharmaceutical, medical device, and biotech sectors, our team excels at overcoming complex challenges. We have successfully supported patient needs and delivered outstanding results for global pharma and biotechs across hundreds of studies.


HiRO's dedication is to become a market-leading, integrated global CRO, partnering closely with biotech and pharmaceutical companies to bring innovative products from the laboratory to the market, providing more effective solutions for patients worldwide.

## Areas of Interest in Taiwan

---

Clinical trials, early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data

management, project management, clinical and medical monitoring



## Company Introduction

---

Novotech, Founded in 1997, has experience in over 5,000 clinical projects from Phase I to Phase IV.

Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 3000 staff globally and 34 office locations.

Novotech provides clinical development services across all clinical trial with the highest quality standards, in line with ICH-GCP, global regulatory agencies and underpinned by robust processes in line with our ISO 9001 accredited Quality Management system.

As a biotech specialist, Novotech has extensive medical, scientific, regulatory, and operational expertise with advanced and novel therapeutics, across all therapeutic areas, including cell & gene therapies, precision medicine, RNA based vaccines and therapeutics, ADCs, microbiome, radiopharmaceuticals and more.

Our geographic presence, our depth of expertise and services, our operational infrastructure, and investments in technological advancements, combine to provide the perfect solution to accelerate global clinical development for biotech Sponsors.


## Areas of Interest in Taiwan

---

Clinical CRO from Phase I to Phase IV (APAC/US/EU) 、 Medical and Regulatory consulting 、 Early Phase Trial in Australia 、 Biometrics and

Data. Management 、 Virtual Trial/DCT/Real World Data 、 Central Lab

# Nucleus Network



👤 Jeffery Wong, Senior Director of Business Development

☎ +61 4 1131 4502

✉ j.wong@nucleusnetwork.com.au

🌐 nucleusnetwork.com

## Company Introduction

---

Nucleus Network is Australia's largest Phase 1 clinical research organisation and the only Phase 1 specialist globally with facilities in the USA and Australia. Since our establishment in 2003, Nucleus Network has conducted well over 1500 Phase 1 clinical trials for some of the most reputable Biotechnology and Pharmaceutical Companies from around the world.

Our facilities are located in Brisbane, Melbourne, and Minneapolis. Combined, our clinics have over 230 beds. All three clinics are strategically co-located within leading medical, research and biotech precincts; the Alfred Hospital in Melbourne, the Royal Brisbane and

Women's Hospital in Brisbane, and Medical Alley in Minneapolis. These precincts offer an expanded capability to administer trials safely and effectively, in partnership with relevant collaborative businesses.

Nucleus specialises in early phase clinical pharmacology clinical trials such as First in human SAD/MAD/FE, DDI, ethnobridging, biosimilar, BE/BA and vaccine programs.

With Australia's beneficial speed, quality and cost outcomes resulting in increased interest from globally, Nucleus Network are looking to create robust, long term business relationships with potential clients and sponsors.

## Areas of Interest in Taiwan

---

Biotechnology Companies, Pharmaceuticals Companies, Early phase clinical trials, Biosimilar, Vaccine

# PCI Pharma Services



👤 Clara Yang, Business Development Executive

☎ 0938 102 571

✉ Clara.yang@pci.com

🌐 pci.com

## Company Introduction

---

PCI is your world leading CDMO, truly spanning the cycle, connecting development and commercialization, de-risking the supply chain providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products' speed to market, and opportunities for commercial success.

PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. Leading technology and continued investment enable us to address global outsourcing development needs throughout the product lifecycle.

PCI offers a global network of innovative centers of excellence for the development, manufacturing, packaging, storage, and distribution of life changing therapies. Our specialist contained manufacturing and packaging facilities dedicated to processing highly potent drug products, combined with our renowned lyophilization and sterile manufacturing capabilities are complemented by a global network of packaging facilities delivering a true end-to-end service. Our aim is simple, to accelerate your product from development to commercialization as efficiently and cost-effectively as possible.

## Areas of Interest in Taiwan

---

Simplifying the clinical supply chain. PCI is committed to supporting clients at every stage of the clinical cycle. As global clinical supply chain experts we provide speed-to-study solutions, unmatched flexibility, and client-centric experience. Providing a seamless

service, we support the global supply of investigational medicines with pharmaceutical development, clinical drug product manufacturing, packaging, labeling, storage, and distribution and full returns service.



# Resonance Health



👤 Carolyn Cheer, Vice President,  
Business Development

☎ +61 0 437 275 054

✉ carolync@resonancehealth.com

🌐 resonancehealth.com

## Company Introduction

---

Resonance Health is a healthcare company specializing in the development and delivery of non-invasive medical imaging software and services. The company's products are used by clinicians in the diagnosis and management of human diseases and by pharmaceutical companies in their clinical trials.


The company's product FerriScan® provides an accurate measurement of liver iron

concentration (LIC) through a non-invasive, MRI-based technology. Likewise, HepaFat® provides an accurate measurement of liver fat content and steatosis grading. A fibrosis tool is currently in proof-of-concept phase and will be available for investigational use in Q3 2024. For clinical trials, we offer a quality assured CRO service for our proprietary products.

## Areas of Interest in Taiwan

---

MRI IMAGING, IRON OVERLOAD DISORDERS, METABOLIC DISEASE, NASH, NAFLD, OBESITY, DIABETES, CKD, IMAGING CRO SERVICES



# Scientia Clinical Research



👤 Chris Stellatos, Director  
Business & Corporate Development

☎ +61 2 9382 5849

✉ [chris.stellatos@scientiaclinicalresearch.com.au](mailto:chris.stellatos@scientiaclinicalresearch.com.au)

🌐 [scientiaclinicalresearch.com.au](http://scientiaclinicalresearch.com.au)

## Company Introduction

---

Scientia Clinical Research (SCR) is a state-of-the-art facility conducting a range of different First Time in Human (FTIH) single and multiple dose studies, drug interaction and other Pharmacokinetic, Biosimilar, Pharmacodynamics and other efficacy studies every year.

Our Unit operates within the Prince of Wales Hospital precinct and we manage approximately 50 clinical trials per year which allows us to ensure consistently high quality data for every project in a timely fashion.

The bulk of our trials are performed in healthy volunteers, but we are unique in that we have a strong track record and history of recruiting oncology, haematology, parkinson's disease, diabetes, fibrosis, atopic dermatitis, NASH and other indications in addition to the healthy volunteers.

The majority of our sponsors are multinational pharmaceutical and biotechnology companies so we maintain an agile and flexible corporate structure, which allows a rapid start-up and recruitment. We are uniquely and with our broad experience across a multitude of study designs, we can reduce study complexity and give your product the best chance for success.

We lead the way in clinical research in Australia. We have arguably the cleanest, most engaged and enthusiastic pool of volunteers and are backed up by the largest and most ethnically diverse city in Australia. With our extensive experience in early phase research, you can be confident that your asset is in the right hands given the high level of personal attention we provide to every project.

## Areas of Interest in Taiwan

---

Early Phase Clinical Trials

# Southern Star Research



David Lloyd, Managing Director  
+61 2 9011 6266  
david@southernstarresearch.com  
southernstarresearch.com

## Company Introduction

Southern Star Research is a leading Australian, privately owned, full-service Contract Research Organisation. We specialise in providing early phase clinical research support to biotech, device and pharmaceutical sponsors looking to accelerate their clinical program in Australia and springboard their clinical program into the US, Europe and South-East Asia. Headquartered in Sydney we actively support studies in Australia, New Zealand, US, Europe and South-East Asia across a range of different therapeutic areas including oncology, Neurology, Endocrinology, Infectious Disease,


Pediatric as well as emerging Cell & Gene Therapies

Full Service CRO:  
Project Management  
Clinical Monitoring & Operations  
Biostatistics & Data Management  
Medical Monitoring & Safety Reporting  
Study Feasibility  
Quality Assurance  
Medical Writing  
Regulatory Affairs  
Local Sponsorship

## Areas of Interest in Taiwan

Seeking to expand our brand and network in Taiwan for 2 reasons: preparing for our expansion into Taiwan and to secure Taiwan

based clients who are interested in running a study in Australia



# St Vincent's Hospital (Melbourne)



**ST VINCENT'S  
HOSPITAL**  
MELBOURNE

A FACILITY OF ST VINCENT'S HEALTH AUSTRALIA

👤 Dr. Tam Nguyen, Deputy Director  
of Research

☎ +61 3 9231 6980

✉ Tam.NGUYEN@svha.org.au

🌐 [svhm.org.au/research/industry/  
research-valet](http://svhm.org.au/research/industry/research-valet)

## Company Introduction

St Vincent's Hospital Melbourne (SVHM) is a major teaching, research and tertiary referral hospital, providing both surgical and medical services. SVHM is dedicated to advancing medical research, with particular focus on translational research to improve clinical practice. SVMH is highly research-active with >1400 clinical research studies (Phase 1 – 4), across all adult clinical areas, for drugs, devices, diagnostics and digital solutions.

### Service

Research Valet® service includes full HREC submission preparation, and liaison throughout

the submission and approval process. The unique feature of this service is close communication between sponsors/researchers and the Research Valet team at each step of the process, offers single point of access for all regulatory advice for Australia.

Research Valet® facilitates all post approval project submission and ongoing ethics management where SVHM is the reviewing HREC. This provides researchers a smooth start up with a highly competitive timeline to gain ethics approval.

## Areas of Interest in Taiwan

Clinical trial site alliance partnership

# Taikun Pharmaceutical Technology



👤 Isaac Huang, Group VP  
☎ +61 4 6689 1508  
✉ isaac.huang@taikunpharma.com  
🌐 taikunpharma.com

## Company Introduction

---

As the expert in global clinical services, Taikun Pharma provides bespoke clinical trial services solutions for our clients.

Whether it's optimizing flexibility in clinical supply timelines or assisting with regulatory guidelines and packaging design, Taikun Pharma is committed to delivering client


centric solutions to support the success of clinical trials globally.

Through our GDP/GMP compliant facilities located in Australia, U.S., Belgium and China, and our partner depot network across South America and Europe, Taikun Pharma provides full range clinical trial services.

## Areas of Interest in Taiwan

---

Pharma Services: Depot & IRT





👤 Bernice Averion, Head of Marketing & Communications

☎ +61 4 1531 1957

✉ Bernice.averion@opyl.ai

🌐 Trialkey.ai

## Company Introduction

---

TrialKey.ai is the market-leading software for clinical trial design optimization and prediction, boasting over 90% accuracy. Usable for any clinical trial worldwide and in any phase, our software improves trial design by an average of 30%, enabling faster, more cost-effective product market entry. As the world's first clinical trial simulator, TrialKey.ai allows companies to design trials, optimize variables, and see real-time impacts on success probabilities, while also benchmarking against competitors.

### Key Features:

- Access to over 350,000 clinical trials, including medical devices and alternative therapies.

- Precise success probability estimates for trials in their current phase.
- A simulator providing near-actual previews of trial performance based on design.
- Competitor view for effective analysis and benchmarking.
- Insights from free-text entries via NLP techniques.
- Custom reports on therapeutic areas or treatments.
- Advanced search, sorting, and filtering functions.
- Comprehensive overviews and timelines of promising research areas.

TrialKey.ai delivers actionable insights to enhance every aspect of trial design, ensuring your clinical trials are efficient and successful.

## Areas of Interest in Taiwan

---

Pharmaceuticals companies, clinical researchers, clinical research organisations, biotech investors, biopharma investors, sites, sponsors

# Taiwanese Companies

# AHEAD Medicine Corporation



👤 Andrea Wang 王毓棠, CEO

☎ +886 2 2371 5617

✉ andrea.wang@aheadmedicine.com

🌐 aheadmedicine.com


## Company Introduction

---

AHEAD Medicine is a pioneering healthtech company. Our flagship solution, Cyto-copilot platform, is revolutionizing flow cytometry data analysis workflow. Cyto-copilot improves the efficiency, reproducibility and scalability of services for disease diagnosis, monitoring, and ensuring quality control in cell therapy.

Cyto-copilot is an AI-enabled data analysis platform technology that revolutionize flow cytometry analysis workflow.

Cyto-copilot provides fast, consistent, adaptable and scalable cytometry analysis for biomedical research development, disease diagnosis/monitoring, and cell therapy quality control.





# BRIM Biotechnology



人 Yi-Lun Chiang 江宜倫, Business Development Manager

☎ +886 2 2659 8586 #120

✉ yilun.chiang@brimbiotech.com

🌐 brimbiotech.com

## Company Introduction

---


BRIM Biotechnology, Inc., founded in 2013 by experienced global pharma experts, is a Taiwan-based company specializing in rapidly developing disease-modifying treatments through integrated translational science. Our unique drug development engine enables efficient progression from discovery to proof of concept (POC). By partnering with top CROs and CMOs, we advance POC-achieved projects to further clinical development.

Our core technology, the Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) platform, has applications in multiple therapeutic areas. It includes three first-in-class assets: BRM421 for Dry Eye Disease, BRM424 for Neurotrophic Keratitis, and BRM521 for Osteoarthritis. This year, we expanded our ophthalmology pipeline by licensing two new drugs: BRM411 for glaucoma and BRM412 for Neovascular glaucoma (NVG). BRIM is committed to advancing these pipelines to benefit patients worldwide.

## Areas of Interest in Taiwan

---

Ophthalmology 、Osteoarthritis



# About Australian Office Commercial Section

The Australian Office Taipei has represented the interests of Australia and Australians in Taiwan for 40 years. The Commercial Section is part of the Australian Trade and Investment Commission (Austrade) and assists Australian companies to expand their international business in Taiwan and attract foreign investment. We do this through providing market research and assistance in identifying and connecting strategic partners.

## 關於澳洲辦事處商務處

澳洲辦事處在台成立 40 年致力於促進澳洲的利益，發展澳洲與台灣之間的合作關係。澳洲辦事處商務處隸屬於澳大利亞貿易和投資委員會（Austrade），協助澳洲公司拓展國際商務到台灣並吸引台商到澳洲投資。我們提供市場分析情報，並協助為台澳廠商媒合商機建立聯繫管道。

To discover how we can help you and your business 想要進一步了解我們提供的協助


請上網 [www.austrade.gov.au/taiwan](http://www.austrade.gov.au/taiwan)


### Contact us 與我們聯繫

---

Duli Chang, Senior Business Development Manager  
T : +886 2 8758 4207  
E : [duli.chang@austrade.gov.au](mailto:duli.chang@austrade.gov.au)

Sam Huang, Business Development Manager  
T : +886 2 8758 4228  
E : [sam.huang@austrade.gov.au](mailto:sam.huang@austrade.gov.au)





澳洲辦事處  
AUSTRALIAN  
OFFICE



AUSTRALIA